|
| Press Releases |
|
 |
|
| Thursday, March 12, 2026 |
|
|
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it is launching an initiative to raise public awareness of the importance of sleep in collaboration with the smartphone application "Pokemon Sleep" more info >> |
|
| Wednesday, March 11, 2026 |
|
|
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting |
| Eisai Co., Ltd. announced today the company will present the latest findings on lecanemab, Eisai's anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer's disease (AD), at the 20th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD(TM) 2026) from March 17-21, in Copenhagen, Denmark, and online. more info >> |
|
| Monday, March 2, 2026 |
|
|
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC) |
| Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada) and Eisai (Headquarters: Tokyo, CEO: Haruo Naito) today announced the first presentation of results from the Phase 3 LITESPARK-011 trial evaluating the dual oral regimen of WELIREG(R) (belzutifan), Merck & Co., Inc., Rahway, NJ, USA's first-in-class oral hypoxiainducible factor-2 alpha (HIF-2a) inhibitor, plus LENVIMA(R) (lenvatinib), an orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, for the treatment of patients with advanced renal cell carcinoma (RCC) whose disease progressed on or after treatment with anti-programmed death receptor-1 (PD-1)/ programmed death-ligand 1 (PD-L1) therapy. more info >> |
|
| Monday, February 16, 2026 |
|
|
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has received an orphan drug designation for its in-house discovered and developed novel selective orexin 2 receptor agonist E2086, with prospective indication for narcolepsy, from the Ministry of Health, Labour and Welfare (MHLW). more info >> |
|
| Tuesday, February 10, 2026 |
|
|
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of "LEQEMBI(R)" (generic name: lecanemab), an anti-amyloid beta (Aβ) protofibril antibody, which was accepted in January 2026, has been designated for Priority Review by the National Medical Products Administration (NMPA) of China. more info >> |
|
| Friday, February 6, 2026 |
|
|
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Shanghai Henlius Biotech, Inc. (Headquarters: Shanghai, China, CEO: Jason Zhu, "Henlius") announced today the conclusion of an exclusive commercialization and co-exclusive development and manufacturing license agreement for the anti-PD-1 antibody serplulimab (generic name, marketed as HANSIZHUANG in China and Hetronifly(R) in the EU) in Japan. more info >> |
|
| Monday, January 26, 2026 |
|
|
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's Supplemental Biologics License Application (sBLA) for lecanemab-irmb (U.S. brand name: LEQEMBI(R)) subcutaneous autoinjector (SC-AI), LEQEMBI IQLIK, as a weekly starting dose. more info >> |
|
| Wednesday, January 21, 2026 |
|
|
Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has been listed in the 2026 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. more info >> |
|
| Tuesday, January 13, 2026 |
|
|
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan |
| Taletrectinib is a highly selective, next-generation oral treatment currently approved for patients living with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) in the U.S., China, and Japan. more info >> |
|
| Tuesday, January 6, 2026 |
|
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
|
| Eisai Co., Ltd. and Biogen Inc. announced today that the Biologics License Application for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of LEQEMBI(R) (generic name: lecanemab), an anti-amyloid beta (Aβ) protofibril antibody, has been accepted by the National Medical Products Administration (NMPA) in China. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Founders Metals Added to GDXJ Index; Commences Drilling at Antino North
Mar 17, 2026 17:59 HKT/SGT
|
|
|
The Executive Centre Advances Digital Transformation in Real Estate with AI Agent Integration 
Mar 17, 2026 16:03 HKT/SGT
|
|
|
Wintermar Reports Results for The Full Year Ended 31 December 2025
Mar 17, 2026 16:36 JST
|
|
|
Successful Flight Demonstration of Mission Autonomy Developed for Use in Unmanned Aerial Vehicles
Mar 17, 2026 14:11 JST
|
|
|
The University of Tokyo and NEC conclude a Strategic Collaboration Agreement to promote a prosperous society where people and AI succeed together
Mar 17, 2026 12:34 JST
|
|
|
NVIDIA Taps 51WORLD as Global L4 Simulation Partner at GTC
Mar 17, 2026 11:02 HKT/SGT
|
|
|
Zylo Ecosystem Announces the Launch of the ZYLO Token to Expand Its Digital Ecosystem
Mar 17, 2026 08:00 HKT/SGT
|
|
|
FinHarbor Introduces Neobank Platform Designed to Go Live in Under 30 Days
Mar 16, 2026 20:30 HKT/SGT
|
|
|
THERMAL-XR(R) Sales in the United States to Commence After GMG Receives U.S. EPA Approval
Mar 16, 2026 19:59 HKT/SGT
|
|
|
Hitachi Energy Japan Recognized as a 2026 Health & Productivity Management Outstanding Organization (Large Enterprise Category)
Mar 16, 2026 16:20 JST
|
|
|
Bonus Savings Account: What It Is and How It Helps You Earn More Interest
Mar 16, 2026 15:10 HKT/SGT
|
|
|
China Lilang Announces 2025 Annual Results
Mar 16, 2026 13:15 HKT/SGT
|
|
|
Fujitsu Japan and Teikyo University Hospital launch joint proof of concept to build mechanism for data analysis and referred-patient management
Mar 16, 2026 12:55 JST
|
|
|
Accelerated Technology Commercialization Drives High-Growth Performance, Qunabox Group Leads the AI Interactive Marketing Track
Mar 16, 2026 10:55 HKT/SGT
|
|
|
FWD Group delivers record full year 2025 results with profitable growth, improved capital and cash flow generation
Mar 16, 2026 10:25 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
